BioScrip (BIOS) Stock Price Down 8%

BioScrip Inc (NASDAQ:BIOS) shares fell 8% during trading on Friday . The stock traded as low as $2.57 and last traded at $2.63. 847,120 shares changed hands during mid-day trading, an increase of 30% from the average session volume of 653,608 shares. The stock had previously closed at $2.86.

Several research firms recently commented on BIOS. Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Wednesday, July 11th. BidaskClub upgraded BioScrip from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 21st. Finally, Barrington Research restated a “buy” rating and set a $4.00 target price on shares of BioScrip in a research report on Friday, October 5th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. BioScrip presently has a consensus rating of “Buy” and an average target price of $3.56.

The stock has a market cap of $337.40 million, a PE ratio of -5.99 and a beta of 0.08.



BioScrip (NASDAQ:BIOS) last announced its earnings results on Tuesday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.10) by ($0.04). The business had revenue of $175.79 million during the quarter, compared to analyst estimates of $169.00 million. Sell-side analysts predict that BioScrip Inc will post -0.32 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of BIOS. Millennium Management LLC raised its stake in shares of BioScrip by 334.4% during the first quarter. Millennium Management LLC now owns 2,425,782 shares of the company’s stock valued at $5,967,000 after acquiring an additional 1,867,415 shares in the last quarter. Rothschild Asset Management Inc. bought a new stake in shares of BioScrip during the second quarter valued at approximately $3,486,000. BlackRock Inc. raised its stake in shares of BioScrip by 14.6% during the second quarter. BlackRock Inc. now owns 7,584,345 shares of the company’s stock valued at $22,222,000 after acquiring an additional 967,219 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of BioScrip by 43.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,962,506 shares of the company’s stock valued at $5,750,000 after acquiring an additional 597,847 shares in the last quarter. Finally, Benefit Street Partners LLC bought a new stake in shares of BioScrip during the second quarter valued at approximately $1,053,000. 84.80% of the stock is owned by hedge funds and other institutional investors.

About BioScrip (NASDAQ:BIOS)

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Story: Marijuana Stocks

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply